Navigation Links
Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19
Date:11/8/2013

(ARM™), in order to assess potential for commercialization. Following this evaluation process, including clinical development, the company may choose to pursue FDA approval through the FDA's Section 505(b)(2) development pathway, or selectively make its treatment options available to the market through pharmacy compounding.  In addition, Imprimis expects to seek partnerships with wholesalers in order to make its drug delivery technologies available to compounding pharmacies across North America.  The company's current focus is in the Ophthalmology, Wound Management, Urology and Pain therapeutic areas.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause Imprimis' results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include Imprimis' ability to enter into licensing arrangements with pharmacies, physicians and healthcare organizations or to otherwise commercialize its formulations, its ability to obtain intellectual property protection for its assets, the success of additional research and development activities related to its formulations, its ability to accurately estimate its expenses and cash burn, its ability to raise additional funds, its ability to acquire, develop, commercialize or market new formulations and to enter into strategic alliances and transactions,  the projected size of the potential market for our product candidates, unexpected new data, safety and technical issues, regulatory and market developments impacting compo
'/>"/>

SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction
2. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
3. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
4. Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013
5. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
6. Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
7. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
8. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
9. Imprimis Announces Key Leadership Appointments
10. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
11. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2, 2014 Research and Markets  has ... Market - Industry Analysis, Size, Share, Growth, Trends and ... The home healthcare market involves wide ... to treat or diagnose a variety of chronic diseases. ... providing cost-effective health care to the patients. Home healthcare ...
(Date:10/2/2014)... , Oct. 2, 2014  Perrigo Company plc (NYSE: ... the laws of Ireland (the " ... exchange (the "Exchange Offer") up to $500,000,000 of its new ... "), $600,000,000 of its new 2.30% Senior Notes due 2018 ... 4.00% Senior Notes due 2023 (the " 2023 Exchange Notes ...
(Date:10/2/2014)... , Oct. 2, 2014   Mast Therapeutics, ... announced today that Edwin L. Parsley , D.O. ... and Senior Vice President.  Dr. Parsley has ... Aires Pharmaceuticals, Inc. in February 2014.  He has served ... and as Chief Medical Officer of Aires since April ...
Breaking Medicine Technology:Global Home Healthcare (Diagnostics and Monitoring Devices, Therapeutic Home Healthcare Devices, Mobility Assist Devices and Medical Supplies) Market - Trends and Forecast, 2014 - 2020 2Global Home Healthcare (Diagnostics and Monitoring Devices, Therapeutic Home Healthcare Devices, Mobility Assist Devices and Medical Supplies) Market - Trends and Forecast, 2014 - 2020 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 4Mast Therapeutics Announces Appointment Of Chief Medical Officer 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 4
... Novavax, Inc. (Nasdaq: NVAX ), a clinical-stage vaccine ... Novavax, will be presenting at the ROTH 23rd Annual OC ... local time at The Ritz Carlton, Laguna Niguel, CA.  A ... via the Company website at www.novavax.com under Investors/Events, ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... the extracellular matrix for the endocrinology, ... financial results for the fourth quarter and year ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) "I am energized and ...
Cached Medicine Technology:Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 2Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 4Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 5Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 6
(Date:10/1/2014)... strongly associated with Alzheimer,s disease; however, researchers are still ... causal agent of the onset and development of the ... beta-amyloid is not harmful when found in isolation but ... to form the so-called amyloid fibrils , "We are ... with multiple ones because each aggregate of peptide, which ...
(Date:10/1/2014)... published today in the Journal of the American ... 50 years with moderate or severe chronic knee pain, ... the University of Melbourne randomly assigned 282 patients (50 ... acupuncture or sham or pretend laser treatment. , ... acupuncturists blinded to laser and sham (inactive) laser acupuncture. ...
(Date:10/1/2014)... Physical Sciences Research Council (EPSRC) will focus on ... systems which run, for example, manufacturing plants, power ... , The research will help understand and ... systems behind our critical national infrastructure. , ... (RITICS), based at Imperial College London, is co-ordinating ...
(Date:10/1/2014)... 2014) Despite a policy focus on expanding ... this vulnerable population continues to have significant dental ... Journal of the American Dental Association , researchers ... University School of Dental Medicine report on the ... oral care provided by caregivers to adults with ...
(Date:10/1/2014)... October 01, 2014 Familylifeinsurancequotes.org has ... life insurance for senior citizens. , Senior citizens ... will now sell coverage to seniors who are over ... be purchased without taking a medical examination. , Term ... online and senior clients can qualify. Having life insurance ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2
... common. Most people are down with at least two to ... could// help reduce the number of infections. , ,According ... after contact with an infected surface and not so much ... advice, that it is imperative to wash hands thoroughly and ...
... have uncovered the role played by a gene associated with the ... for its role in diabetes and obesity, explained Michel L. Tremblay, ... ,Their study, published in the magazine Nature Genetics, shows that ... slowed the growth of - and in some cases, prevented - ...
... in different Kerala jails will perform a three-hour programme before ... is for the first time in Kerala that prisoners are ... of Police G. Baburaj told reporters here Monday., ... besides that they also have a social urge and we ...
... with Parkinson’s disease in 15 of the world’s largest nations ... study were published in the January 30 issue of the ... facing countries with rapidly growing economies, particularly in Asia, many ... health threat. ,In recent years, a great deal ...
... disclosed that suppression of an enzyme called PTP1B stalls ... This study was conducted on laboratory mice which were ... of humans. ,This research headed by Michel ... Quebec delayed the advancement of a particular kind of ...
... that throws light on the extent of neurological ailments in ... reams of medical research, Deborah Hirtz, and colleagues from the ... the most common and treated neurological diseases in the country. ... from the last 15 years and indexed the diseases according ...
Cached Medicine News:Health News:Worldwide Parkinson's Cases To Double In Next 25 Years 2Health News:Worldwide Parkinson's Cases To Double In Next 25 Years 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: